Phase I Study of the BRAF Inhibitor Vemurafenib in Combination With the Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With BRAF-Mutated Malignancies

PURPOSE: Parallel activation of the phosphatidylinositol 3-kinase–mammalian target of rapamycin pathway represents a mechanism of primary and acquired resistance to BRAF-targeted therapy, but the two pathways have yet to be cotargeted in humans. We performed a phase I study to evaluate the safety an...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:JCO Precis Oncol
Κύριοι συγγραφείς: Subbiah, Vivek, Sen, Shiraj, Hess, Kenneth R., Janku, Filip, Hong, David S., Khatua, Soumen, Karp, Daniel D., Munoz, Javier, Falchook, Gerald S., Groisberg, Roman, Tsimberidou, Apostolia M., Sherman, Steven I., Hwu, Patrick, Meric-Bernstam, Funda
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: American Society of Clinical Oncology 2018
Θέματα:
Original Report
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7446411/
https://ncbi.nlm.nih.gov/pubmed/32913986
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/PO.18.00189
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια